MP74-13 LONG TERM OUTCOMES OF COVID-19 ASSOCIATED CYSTITIS (CAC) (2023)

You have accessJournal of UrologyCME1 Apr 2023MP74-13 LONG TERM OUTCOMES OF COVID-19 ASSOCIATED CYSTITIS (CAC) Sina Mehraban-Far, Sorabh Dhar, Michael Chancellor, Samer Kirmiz, Steven Lucas, and Nivedita Dhar Sina Mehraban-FarSina Mehraban-Far More articles by this author , Sorabh DharSorabh Dhar More articles by this author , Michael ChancellorMichael Chancellor More articles by this author , Samer KirmizSamer Kirmiz More articles by this author , Steven LucasSteven Lucas More articles by this author , and Nivedita DharNivedita Dhar More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003348.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: COVID-19 associated cystitis (CAC) is a newly-described condition associated with new onset or exacerbations of baseline urinary symptoms (e.g. overactive bladder (OAB) symptoms) that may present as a manifestation of Long COVID. Little is known on the management and long-term outcomes for patients suspected of having CAC. In this study we aim to assess the long term efficacy of conservative OAB the on their symptoms. METHODS: In this prospective cohort study, we identified patients with CAC 10-14 weeks following discharge from 2 academic downtown Detroit hospitals with new or worsening OAB during 5/22/2020 to 12/31/2020. Symptoms were assessed at baseline and at 21-28 months post-discharge using the AUA’s 5 symptom OAB assessment tool and 4 quality-of-life (QoL) symptoms, based on gender and changes in urinary symptom status. RESULTS: A total of 350 patients with CAC were identified, of which 250 (71%) had new onset, and 100 (29%) had worsening OAB symptoms after COVID hospitalization (Table 1). Follow up at 21-28 months revealed significant decreases in median OAB and QoL scores for all groups (Table 2). Overall, 270 (87%) of the 310 patients improved with standard therapies (e.g. behavioral modification), with a decrease in the OAB and Qol score from 18 and 19 to 7 and 8 respectively. Of the 250 patients with new onset symptoms, 220 (95.4%) had improvement in symptoms, whereas, of those with existing OAB symptoms only 60 (60.7%) improved. In the later, OAB and Qol scores decreased by 6 points compared with 9-10 in the new onset group, with a lack of return to baseline status. No differences were noted among improvements in symptoms between females and males. CONCLUSIONS: We hereby report the first long-term follow-up of patients who developed CAC and assessed the prognosis of CAC in Long COVID. We found that after 21-28 months, only 13% (40/310) of patients had persistent lower urinary tract symptoms. Patients with Long COVID and CAC may be reassured that symptoms resolves in vast majority of cases and that supportive and reversible treatment should be recommended. Source of Funding: NA © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1074 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sina Mehraban-Far More articles by this author Sorabh Dhar More articles by this author Michael Chancellor More articles by this author Samer Kirmiz More articles by this author Steven Lucas More articles by this author Nivedita Dhar More articles by this author Expand All Advertisement PDF downloadLoading ...